EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade

Hiroyuki Uchida iD, Gabriella Gobbi iD, Joseph Zohar iD, Allan H Young, Dan Rujescu, Ming-Chyi Huang iD, Suresh Sundram, Lukoye Atwoli, Jana Vukovic, Kazutaka Ikeda

International Journal of Neuropsychopharmacology · 10.08.2026 · 29 (8)

DOI: 10.1093/ijnp/pyag023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 07.05.2026. Verfasst von Hiroyuki Uchida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Keio University School of Medicine (International College of Neuropsychopharmacology, CINP), Tokyo, Japan. Hauptthemen laut MEDLINE: Central Nervous System Agents, Drug Discovery, Drug Development. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology.

Methods

We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence, genetics, artificial intelligence (AI), and implementation/global-access themes that are endorsed by international societies.

Results

Therapeutic gains include rapid-acting drugs for treatment-resistant depression (intranasal esketamine); psychedelic-assisted therapy for posttraumatic stress disorder and depression; neuroactive steroid γ-aminobutyric acid-A receptor positive allosteric modulators (brexanolone, zuranolone) for postpartum depression; non-dopaminergic muscarinic agonists (xanomeline–trospium) for schizophrenia; orexin receptor antagonists for insomnia; and anti-amyloid monoclonal antibodies (lecanemab, donanemab) for early Alzheimer’s disease. Persistent barriers include high mid-/late-stage attrition that is driven by placebo effects, subjective endpoints, and preclinical-to-clinical gaps; regulatory and economic headwinds; and limited generalizability from tightly run trials. Emerging enablers include adaptive/platform designs, digital health technologies, patient-reported outcomes, and clinical outcome assessments, real-world evidence (RWE), AI/machine learning (ML), genetics for target de-risking and biomarker-guided stratification, and publicly accessible large CNS relevant biological datasets.

Conclusions

To convert momentum into durable progress, we recommend: (1) deeper academia–industry/stakeholder collaboration and sustained funding for high-risk/high-reward science from industry, governments, and non-for profit foundations; (2) modernized regulation (flexible evidentiary paths, novel endpoints, and clear guidance on adaptive/platform trials); (3) data-driven development integrating RWE, AI/ML, and precision medicine; (4) the adoption of Neuroscience-based Nomenclature; and (5) a global-access mandate with essential-medicine inclusion, equitable pricing/licensing, capacity building, tele-enabled mental health, and geographically diverse research. Aligning scientific innovation with implementation and equity can accelerate translation and ensure new treatments benefit patients worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System AgentsDrug DiscoveryDrug DevelopmentHumansAnimals

Stichwörter der Autor:innen

CNS drug developmentneuropsychopharmacologyprecision medicine

Substanzen

Central Nervous System Agents

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Keio University School of Medicine (International College of Neuropsychopharmacology, CINP), Tokyo, Japan.
  • Department of Psychiatry, McGill University (CINP), Montreal, Canada.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, and National Post-Trauma Center, Sheba Medical Center (CINP), Ramat Gan, Israel.
  • Department of Brain Sciences, Imperial College London (CINP), London, United Kingdom.
  • Department of Psychiatry, Medical University of Vienna (CINP), Vienna, Austria.
  • Taipei City Psychiatric Center, Taipei City Hospital and Department of Psychiatry, Taipei Medical University (CINP), Taipei, Taiwan.

ORCID-Profile: Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar, Ming-Chyi Huang

Zitieren

APA

Uchida, H., Gobbi, G., Zohar, J., Young, A. H., Rujescu, D., Huang, M. C., Sundram, S., Atwoli, L., Vukovic, J., & Ikeda, K. (2026). Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade. International Journal of Neuropsychopharmacology, 29(8). https://doi.org/10.1093/ijnp/pyag023

Vancouver

Uchida H, Gobbi G, Zohar J, Young AH, Rujescu D, Huang MC, et al. Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade. International Journal of Neuropsychopharmacology. 2026;29(8). doi:10.1093/ijnp/pyag023

BibTeX
@article{Uchida2026,
  author = {Uchida, Hiroyuki and Gobbi, Gabriella and Zohar, Joseph and Young, Allan H and Rujescu, Dan and Huang, Ming-Chyi and Sundram, Suresh and Atwoli, Lukoye and Vukovic, Jana and Ikeda, Kazutaka},
  title = {Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {8},
  doi = {10.1093/ijnp/pyag023}
}
Kostenlos starten →